Group 1 - The core viewpoint of the article highlights Shenzhen Kangtai Biological Products Co., Ltd.'s transformation into a global innovative biopharmaceutical company, with significant growth in R&D investment and overseas business revenue [1][2] - In 2025, the company expects a net profit attributable to shareholders of between 49 million to 73 million yuan, with overseas business revenue reaching approximately 98.84 million yuan, reflecting a year-on-year growth of 859.40% [1] - R&D investment is projected to be around 633 million yuan, marking an 11.25% increase compared to the previous year [1] Group 2 - The company has made key progress in expanding its overseas market, with multiple core vaccine products obtaining overseas GMP certification or registration, covering over 20 countries [2] - Kangtai Biological is leveraging AI technology to enhance vaccine innovation, participating in industry exchanges and establishing a key laboratory in collaboration with the Chinese Academy of Sciences [2] - The company aims to accelerate its transformation by focusing on R&D-driven strategies, deepening international layouts, and embracing AI to enhance the entire vaccine development and production process [3]

证券日报网讯 1月29日，诺诚健华在互动平台回答投资者提问时表示，公司上市以来管线推进迅速，营 业收入实现加速增长，根据公司业绩预告，公司预计2025年度首次实现扭亏为盈，预计2025年实现营业 总收入人民币23.65亿元左右，与上年同期相比增长134%左右，归属于母公司所有者的净利润为6.33亿 元左右。 （编辑 姚尧） ...

（编辑 姚尧） 证券日报网讯 1月29日，诺诚健华在互动平台回答投资者提问时表示，公司与Zenas交易不仅为公司带 来了实质性的即期财务收益，进一步增强了公司的现金储备与资产结构，里程碑付款可以为公司带来可 持续的现金流与长期收益，此次合作也将有助于最大化奥布替尼在全球范围内的临床与商业价值，使产 品能够更快惠及全球患者，也充分体现了公司创新资产的国际竞争力与长期商业潜力。公司未来也会持 续推进全球化战略，以"自主创新+合作共赢"的模式加速创新成果在全球范围的临床开发与商业转化。 ...

Core Viewpoint - ST Unimed (002581.SZ) forecasts a significant loss for the fiscal year 2025, with projected revenue between 355 million to 398 million yuan and a net loss attributable to shareholders ranging from 55 million to 90 million yuan, compared to a loss of 137 million yuan in the same period last year [1] Financial Performance - The company expects to report a revenue of 355 million to 398 million yuan for the fiscal year 2025 [1] - The net loss attributable to shareholders is projected to be between 55 million to 90 million yuan, an improvement from the previous year's loss of 137 million yuan [1] - The net profit after deducting non-recurring gains and losses is anticipated to be a loss of 70 million to 105 million yuan, compared to a loss of 111 million yuan in the previous year [1] Operational Challenges - The primary reason for the company's losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has adversely affected related business revenue [1] - The company is actively working on rectification to promote the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]

Group 1 - The company, I-Woo Bio (300357), stated that it will fulfill its information disclosure obligations according to the relevant requirements of the "Performance Forecast and Performance Express" section of the Shenzhen Stock Exchange's Growth Enterprise Market listing rules [1]

2025年，公司临床前管线转化也取得关键进展，两款具有创新性的临床前候选药物，WRN抑制剂 YF087和KIF18A抑制剂YF550在多项临床前研究中展现出优秀的抗肿瘤潜力，目前正在开展IND支持性 研究，为后续进入临床阶段做准备;与此同时，公司持续投入早期研发，包括其他候选药物的开发、创 新技术平台建设以及药物的早期发现，为长期发展积蓄动力。 益方生物(688382.SH)发布2025年年度业绩预亏公告，预计2025年度实现归属于母公司所有者净亏损2.92 亿元。 2025年度，公司业绩变化主要受到研发投入强度与营收构成的共同影响。随着研发管线的扎实推进，多 个核心临床项目已进入关键阶段，并取得积极进展，研发投入维持在较高水平：口服选择性雌激素受体 降解剂(SERD)D0502正在国内开展二线治疗注册III期临床试验;TYK2抑制剂D-2570已启动多个自身免疫 性疾病领域的临床探索，包括正在国内开展的溃疡性结肠炎II期临床试验、银屑病注册III期临床试验， 以及在美国开展的I期临床试验等;URAT1抑制剂D-0120在美国开展的联合用药II期临床试验于报告期内 完成随访，预计将于2026年第一季度完成全部 ...

格隆汇1月29日丨ST未名(002581.SZ)发布2025年度业绩预告，报告期内，实现营业收入3.55亿元-3.98亿 元；归属于上市公司股东的净利润为亏损5,500万元-9,000万元，上年同期亏损1.37亿元；扣除非经常性 损益后的净利润为亏损7,000万元-1.05亿元，上年同期亏损1.11亿元。 本报告期内公司业绩亏损主要原因为控股子公司天津未名生物医药有限公司暂停生产和销售，相关业务 收入受到影响。同时，为推进复产进程，公司积极整改，成本与费用支出持续，导致亏损。 ...

Core Viewpoint - 康诺生物制药股份有限公司 is preparing for an IPO on the Hong Kong Stock Exchange, with significant revenue fluctuations and a focus on mitochondrial medicine and health products [1][2][5]. Group 1: Company Overview - 康诺生物, established in 2017, specializes in the research and commercialization of drugs related to mitochondrial dysfunction, targeting cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [5]. - The market for mitochondrial medicine products in China is projected to grow from 95 billion yuan in 2020 to 179 billion yuan by 2024, with a compound annual growth rate (CAGR) of 17.1%, and expected to reach 308.1 billion yuan by 2035, with a CAGR of 29.5% from 2024 to 2035 [5]. Group 2: Financial Performance - 康诺生物's revenue for 2023 and 2024 was 3.03 billion yuan and 2.4 billion yuan, respectively, representing a decline of approximately 20.8%, while net profit dropped by 57.4% to 795.2 million yuan and 339.05 million yuan [6]. - In the first three quarters of 2025, the company reported a revenue of 238 million yuan, a year-on-year increase of 33%, and a net profit of 53.41 million yuan, up 93% [7]. Group 3: Product Portfolio - The flagship product, 恩艾地 (NAD⁺ injection), accounted for 65.2% of total revenue in the first three quarters of 2025, with revenues of 134 million yuan, 106 million yuan, and 155 million yuan in 2023, 2024, and 2025 respectively [9]. - The company has a total of 20 commercialized drugs, with 15 included in the national medical insurance directory, but 恩艾地 is not among them, which could impact future revenues if it is included [10]. Group 4: Future Prospects and R&D - 康诺生物 plans to use IPO proceeds to fund the development of several candidate drugs, including those targeting acute myocardial infarction and chronic heart failure, with clinical trials expected to complete by Q1 2027 [11]. - The company also aims to invest in the construction of smart biological factories and upgrade its sales and distribution networks, as well as digital infrastructure [11].

Core Viewpoint - Zhixiang Jintai (688443.SH) forecasts a net loss attributable to shareholders of the parent company for 2025, ranging from -480.64 million to -587.45 million yuan, representing a year-on-year reduction in losses by 209.83 million to 316.64 million yuan, or a decrease of 26.32% to 39.71% [1] Group 1: Financial Performance - The company's operating revenue is expected to significantly increase compared to the previous year, primarily due to steady sales growth of its first commercial product, Saliqi monoclonal antibody injection (Jinlixi), and revenue from the authorization license and commercialization agreement for GR1803 injection [1] - The reduction in net loss is attributed to the absence of share-based payment expenses in 2025, as the equity incentive plan for the core team implemented in 2022 will expire in 2024 [1] Group 2: Research and Development - The company continues to focus on original innovation and efficiently advancing the progress of various research projects, with multiple products entering clinical research and core products entering critical clinical trial phases [1] - The company maintains a high level of R&D investment in its ongoing projects [1]

2026.01. 29 本文字数：1466，阅读时长大约3分钟 作者 | 第一财经 林志吟 中国人用疫苗（下称疫苗）出口金额在2024年恢复正增长后，2025年再度出现增长，且增速进一步 提高。 中国医药保健品进出口商会1月29日在公众号上发布的数据显示，2025年，中国疫苗出口金额为 3.24亿美元，同比增长52.63%。 回顾2024年，中国疫苗出口金额为2.12亿美元，同比增长4.92%，彼时是2022年以来首次恢复正 增长，摆脱了过去三年受抗击新冠疫情需求变化而带来的波动影响。 2025年，中国人用疫苗出口到了全球85个市场，前十大市场出口金额占比为70.04%。其中，对巴 基斯坦出口同比增长130.53%，对巴西出口同比增长为119.50%，对缅甸出口增幅甚至高达近30 倍。 长期以来，国内许多疫苗企业聚焦成熟度高且市场风险较小的传统技术路线产品，Me-too（同类仿 创）类管线占比高，且大多集中在宫颈癌疫苗、肺炎球菌疫苗和脑膜炎球菌疫苗等热门疫苗品种，重 磅产品上市时间显著晚于欧美头部企业，进而导致国内疫苗存量市场竞争持续加剧、产品同质化竞争 日益明显。 面对国内疫苗市场竞争愈演愈烈背景下，越来越 ...